Ryan Sun, Ph.D.
Department of Biostatistics, Division of Discovery Science
About Dr. Ryan Sun
For more information and software downloads, please see Dr. Sun's personal website
::::::::::https://ryanrsun.github.io.
Read More
Present Title & Affiliation
Primary Appointment
Adjunct Assistant Professor, Department of Statistics, Division of Discovery Science, Rice University, Houston, Texas
Assistant Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | Harvard University, Boston, Massachusetts, US, Ph.D. in Biostatistics |
| 2014 | Harvard University, Boston, Massachusetts, US, MA in Biostatistics |
| 2012 | Columbia University, New York, New York, US, BS in Applied Mathematics |
Postgraduate Training
| 2017-2019 | Research Fellowship, Harvard University, Boston, Massachusetts |
Experience & Service
Administrative Appointments/Responsibilities
Course Director, GS 1023 (Survival Analysis), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Other Appointments/Responsibilities
Advisory Board, Boehringer Ingelheim, 2021 - 2022
Consultant, Blue Null Consulting Group, 2019 - Present
Institutional Committee Activities
Member, MD Anderson GSBS Admissions Committee, 2022 - 2023
Member, Multidisciplinary Research Program Biostatistics Review Committee, 2022 - Present
Member, Department of Biostatistics Visiting Guest Lecturer Committee, 2021 - Present
Member, ARTEMIS Breast Cancer Trial Resource Committee, 2021 - 2023
Member, Breast Cancer Moonshot Steering Committee, 2021 - 2022
Member, Scientific Review Committee 4, 2020 - Present
Member, GSBS Curriculum Committee, 2020 - 2021
Member, Lymphoma/Myeloma Immune Effector Cell Steering Committee, 2020 - Present
Member, Biostatistics Protocol Review Committee, 2020 - Present
Member, GSBS Biostatistics Admissions Subcommittee, 2019 - Present
Member, Young Faculty Committee, 2019 - 2022
Honors & Awards
| Lauren P. Breakiron Scholar, Columbia University | |
| Cyprus Travel Grant, Harvard-Cyprus Program | |
| Distinction in Teaching Award, Harvard University | |
| Postdoctoral Travel Award, Harvard Program in Quantitative Genomics | |
| Distinguished Student Paper Award, Eastern North Atlantic Region of the International Biometric Society (ENAR) | |
| New Researchers Conference Travel Award, Institute of Mathematical Statistics |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Sun R, McCaw Z, Lin X. Testing a Large Number of Composite Null Hypotheses Using Conditionally Symmetric Multidimensional Gaussian Mixtures in Genome-Wide Studies. J Am Stat Assoc None(None):None. e-Pub 2024. PMID: None.
- Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res None(None):None, 2024. PMID: 39133081.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. PMID: 38381705.
- Antonoff, MB, Kui, N, Sun, R, Deboever, N, Hofstetter, WL, Mehran, RJ, Morris, VK, Rice, DC, Swisher, SG, Vaporciyan, AA, Walsh, GL, Rajaram, R. Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer. Journal of Thoracic and Cardiovascular Surgery 168(1):263-271, 2024. PMID: 37690624.
- Choi J, Xu Z, Sun R. Variance-components tests for genetic association with multiple interval-censored outcomes. Stat Med 43(13):2560-2574, 2024. PMID: 38636557.
- Scott H, Alvarez PE, Howell RM, Riegel A, Sun R, Liu K, Kry SF. Chromatic bleaching and fractionation effects on optically stimulated luminescent dosimeter reuse. Med Phys None(None):None, 2024. PMID: 38852196.
- Hsu, EJ, Lin, TA, Dabush, DR, McCaw, ZR, Koong, A, Lin, C, Abi Jaoude, J, Patel, RR, Kouzy, R, El Alam, MB, Noticewala, SS, Yang, Y, Sherry, AD, Fuller, C, Thomas, CR, Tang, C, Msaouel, P, Das, P, Huang, B, Tian, L, Sun, R, Lee, JJ, Meirson, T, Ludmir, EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. Journal of the National Cancer Institute 116(6):990-994, 2024. PMID: 38331394.
- Chamseddine, SM, Lapelusa, M, Carter, K, Nguyen, V, Mohamed, YI, Sakr, Y, Rojas Hernandez, CM, Hatia, RI, Hassan, MM, Goss, JA, Elsayes, KM, Rashid, A, Sun, R, Cao, HT, Amin, H, Kaseb, A. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. Journal of Gastrointestinal Oncology 15(3):1324-1330, 2024. PMID: 38989410.
- Bahrambeigi, V, Lee, JJ, Branchi, V, Rajapakshe, K, Xu, Z, Kui, N, Henry, JT, Kun, W, Stephens, BM, Dhebat, S, Hurd, MW, Sun, R, Yang, P, Ruppin, E, Wang, W, Kopetz, S, Maitra, A, Guerrero, PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. Cancer Research 84(10):1719-1732, 2024. PMID: 38451249.
- Jallouk, AP, Kui, N, Sun, R, Westin, JR, Steiner, RE, Nair, R, Nastoupil, L, Fayad, LE, Zaki, AA, Hawkins, MC, Adkins, S, Noorani, M, Das, K, Henderson, J, Shpall, E, Kebriaei, P, Ramdial, JL, Flowers, CR, Neelapu, SS, Ahmed, S, Strati, P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. PMID: 38031807.
- Hornstein, N, Zeineddine, MA, Gunes, BB, Pellatt, AJ, Knafl, M, Zhu, H, Willett, A, Yousef, A, Liu, S, Sun, R, Futreal, A, Woodman, SE, Taggart, MW, Overman, MJ, Halperin, DM, Raghav, KS, Shen, JY. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Research Communications 4(5):1363-1368, 2024. PMID: 38709066.
- Li, Y, Xiao, X, Li, J, Han, Y, Cheng, C, Fernandes, GF, Slewitzke, SE, Rosenberg, SM, Zhu, M, Byun, J, Bossé, Y, McKay, J, Albanes, D, Lam, S, Tardón, A, Chen, C, Bojesen, SE, Landi, MT, Johansson, M, Risch, A, Bickeböller, H, Wichmann, He, Christiani, DC, Rennert, G, Arnold, SM, Goodman, G, Field, JK, Davies, MP, Shete, S, Le Marchand, L, Liu, G, Hung, RJ, Andrew, AS, Kiemeney, L, Sun, R, Zienolddiny, S, Grankvist, K, Johansson, M, Caporaso, N, Cox, A, Hong, YC, Lazarus, P, Schabath, MB, Aldrich, MC, Schwartz, AG, Gorlov, IP, Purrington, K, Yang, P, Liu, Y, Bailey-Wilson, J, Pinney, SM, Mandal, D, Willey, J, Gaba, C, Brennan, P, Xia, J, Shen, H, Amos, CI. Lung Cancer in Ever- and Never-Smokers. Cancer Epidemiology Biomarkers and Prevention 33(3):389-399, 2024. PMID: 38180474.
- Zhu H, Choi J, Kui N, Yang T, Wei P, Li D, Sun R. Identification of Pancreatic Cancer Germline Risk Variants With Effects That Are Modified by Smoking. JCO Precis Oncol 8:e2300355, 2024. PMID: 38564682.
- Sun R, Shi A, Lin X. Differences in set-based tests for sparse alternatives when testing sets of outcomes compared to sets of explanatory factors in genetic association studies. Biostatistics 25(1):171-187, 2024. e-Pub 2022. PMID: 36000269.
- Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. PMID: 37822075.
- Zeineddine, F, Zeineddine, MA, Yousef, A, Gu, Y, Chowdhury, S, Dasari, NV, Huey, RW, Johnson, B, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Overman, MJ, Parseghian, C, Raghav, KS, Willis, JA, Wolff, RA, Kawaguchi, Y, Vauthey, JN, Sun, R, Kopetz, S, Shen, JY. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology 7(1), 2023. PMID: 36781990.
- Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Zhang Z, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer 11(11):None, 2023. PMID: 38007239.
- Sherry, AD, Msaouel, P, McCaw, ZR, Abi Jaoude, J, Hsu, EJ, Kouzy, R, Patel, RR, Yang, Y, Lin, TA, Taniguchi, C, Rödel, C, Fokas, E, Tang, C, Fuller, C, Minsky, B, Meirson, T, Sun, R, Ludmir, EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials. European Journal of Cancer 194, 2023. PMID: 37827064.
- Chamseddine, SM, Mohamed, Y, Lee, SS, Yao, JC, Hu, Z, Tran Cao, HS, Xiao, L, Sun, R, Morris, J, Hatia, RI, Hassan, MM, Duda, DG, Diab, M, Mohamed, A, Nassar, A, Datar, S, Amin, H, Kaseb, A. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology (Switzerland) 101(11):730-737, 2023. PMID: 37467732.
- Sun R, Sun D, Zhu L, Sun J. Regression analysis of general mixed recurrent event data. Lifetime Data Anal 29(4):807-822, 2023. PMID: 37438585.
- Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7(None):e2300228, 2023. PMID: 37824798.
- Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
- Wang, H, Moniruzzaman, R, Li, L, Ji, B, Liu, Y, Zuo, X, Abbasgholizadeh, R, Zhao, J, Liu, G, Wang, R, Tang, H, Sun, R, Su, X, Tan, TH, Maitra, A, Wang, H. Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia. Journal of Clinical Investigation 133(12), 2023. PMID: 37140994.
- Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
- McCaw ZR, Gaynor SM, Sun R, Lin X. Leveraging a surrogate outcome to improve inference on a partially missing target outcome. Biometrics 79(2):1472-1484, 2023. PMID: 35218565.
- Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
- Sun R, Zhu L, Li Y, Yasui Y, Robison L. Inference for Set-Based Effects in Genetic Association Studies with Interval Censored Outcomes. Biometrics 79(2):1573-1585, 2023. PMID: 35165890.
- Sohn AJ, Taherian M, Katz MHG, Prakash LR, Chatterjee D, Wang H, Kim M, Tzeng CD, Lee JE, Ikoma N, Rashid A, Wolff RA, Zhao D, Koay EJ, Sun R, Maitra A, Wang H. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol 47(4):421-430, 2023. e-Pub 2023. PMID: 36746143.
- Han Y, Byun J, Zhu C, Sun R, Roh JY, Cordell HJ, Lee HS, Shaw VR, Kang SW, Razjouyan J, Cooley MA, Hassan MM, Siminovitch KA, Folseraas T, Ellinghaus D, Bergquist A, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Study Group IP, McGlynn KA, Roberts LR, Amos CI. Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. Nat Commun 14(1):1069, 2023. e-Pub 2023. PMID: 36828809.
- Patni T, Lee CT, Li Y, Kaste S, Zhu L, Sun R, Hudson MM, Ness KK, Neumann A, Robison LL. Factors for poor oral health in long-term childhood cancer survivors. BMC Oral Health 23(1):73, 2023. e-Pub 2023. PMID: 36739372.
- Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
- Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2022. PMID: 36351210.
- Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy with Cetuximab in Advanced Colorectal Cancer. Journal of Clinical Oncology 41(3):472-478, 2023. PMID: 36067452.
- Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. PMID: 37389847.
- Li, X, Quick, C, Zhou, H, Gaynor, SM, Liu, Y, Chen, H, Selvaraj, MS, Sun, R, Dey, R, Arnett, DK, Bielak, LF, Bis, JC, Blangero, J, Boerwinkle, E, Bowden, DW, Brody, JA, Cade, BE, Correa, A, Cupples, LA, Curran, JE, de Vries, PS, Duggirala, R, Freedman, BI, Göring, HH, Guo, X, Haessler, J, Kalyani, RR, Kooperberg, C, Kral, BG, Lange, LA, Manichaikul, AW, Martin, LW, McGarvey, ST, Mitchell, BD, Montasser, ME, Morrison, AC, Naseri, T, O’Connell, JR, Palmer, ND, Peyser, PA, Psaty, BM, Raffield, LM, Redline, S, Reiner, AP, Reupena, MS, Rice, K, Rich, SS, Sitlani, CM, Smith, JA, Menon, VK. Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies. Nature Genetics 55(1):154-164, 2023. PMID: 36564505.
- Li, Z, Li, X, Zhou, H, Gaynor, SM, Selvaraj, MS, Arapoglou, T, Quick, C, Liu, Y, Chen, H, Sun, R, Dey, R, Arnett, DK, Auer, PL, Bielak, LF, Bis, JC, Blackwell, T, Blangero, J, Boerwinkle, E, Bowden, DW, Brody, JA, Cade, BE, Conomos, MP, Correa, A, Cupples, LA, Curran, JE, de Vries, PS, Duggirala, R, Franceschini, N, Freedman, BI, Göring, HH, Guo, X, Kalyani, RR, Kooperberg, C, Kral, BG, Lange, LA, Lin, BM, Manichaikul, AW, Manning, AK, Martin, LW, Mathias, R, Meigs, JB, Mitchell, BD, Montasser, ME, Morrison, AC, Naseri, T, O'connell, Jr, Palmer, ND, Peyser, PA, Psaty, BM, Raffield, LM. A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies. Nature Methods 19(12):1599-1611, 2022. PMID: 36303018.
- Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
- Huang B, Sun R, Claggett B, Tian L, Ludmir EB, Wei LJ. Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. JAMA Oncol 8(10):1502-1503, 2022. PMID: 35980612.
- Li Y, Xiao X, Li J, Byun J, Cheng C, Bossé Y, McKay J, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböller H, Wichmann HE, Christiani DC, Rennert G, Arnold S, Goodman G, Field JK, Davies MPA, Shete SS, Le Marchand L, Melander O, Brunnström H, Liu G, Hung RJ, Andrew AS, Kiemeney LA, Shen H, Sun R, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Teare DM, Hong YC, Lazarus P, Schabath MB, Aldrich MC, Schwartz AG, Gorlov I, Purrington K, Yang P, Liu Y, Han Y, Bailey-Wilson JE, Pinney SM, Mandal D, Willey JC, Gaba C, Brennan P, Amos CI, cancer consortium IL. Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. Hum Mol Genet 31(16):2831-2843, 2022. PMID: 35138370.
- Byun J, Han Y, Li Y, Xia J, Long E, Choi J, Xiao X, Zhu M, Zhou W, Sun R, Bossé Y, Song Z, Schwartz A, Lusk C, Rafnar T, Stefansson K, Zhang T, Zhao W, Pettit RW, Liu Y, Li X, Zhou H, Walsh KM, Gorlov I, Gorlova O, Zhu D, Rosenberg SM, Pinney S, Bailey-Wilson JE, Mandal D, de Andrade M, Gaba C, Willey JC, You M, Anderson M, Wiencke JK, Albanes D, Lam S, Tardon A, Chen C, Goodman G, Bojeson S, Brenner H, Landi MT, Chanock SJ, Johansson M, Muley T, Risch A, Wichmann HE, Bickeböller H, Christiani DC, Rennert G, Arnold S, Field JK, Shete S, Le Marchand L, Melander O, Brunnstrom H, Liu G, Andrew AS, Kiemeney LA, Shen H, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Cox A, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Patel A, Lan Q, Rothman N, Taylor F, Kachuri L, Witte JS, Sakoda LC, Spitz M, Brennan P, Lin X, McKay J, Hung RJ, Amos CI. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet 54(8):1167-1177, 2022. e-Pub 2022. PMID: 35915169.
- Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. PMID: 35512184.
- Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res 28(13):2878-2889, 2022. PMID: 35507014.
- Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
- Li X, Yung G, Zhou H, Sun R, Li Z, Hou K, Zhang MJ, Liu Y, Arapoglou T, Wang C, Ionita-Laza I, Lin X. A multi-dimensional integrative scoring framework for predicting functional variants in the human genome. Am J Hum Genet 109(3):446-456, 2022. e-Pub 2022. PMID: 35216679.
- Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
- Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, Muffly L. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv 6(5):1608-1618, 2022. PMID: 34610109.
- Alhalabi, O, Soomro, Z, Sun, R, Hasanov, E, Albittar, A, Tripathy, D, Valero, V, Ibrahim, NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. npj Breast Cancer 7(1), 2021. PMID: 33742001.
- Sun R, McCaw Z, Tian L, Uno H, Hong F, Kim DH, Wei LJ. Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer 9(11), 2021. PMID: 34799398.
- Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. PMID: 34253579.
- Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
- Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. PMID: 33534891.
- Bhamidipati, D, Colina, A, Hwang, H, Wang, H, Katz, MH, Fournier, KF, Serpas Higbie, V, Thomas, J, Sun, R, Wolff, RA, Raghav, KS, Overman, MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3), 2021. PMID: 33940348.
- Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. PMID: 32984932.
- Sun R, Xu M, Li X, Gaynor S, Zhou H, Li Z, Bossé Y, Lam S, Tsao MS, Tardon A, Chen C, Doherty J, Goodman G, Bojesen SE, Landi MT, Johansson M, Field JK, Bickeböller H, Wichmann HE, Risch A, Rennert G, Arnold S, Wu X, Melander O, Brunnström H, Le Marchand L, Liu G, Andrew A, Duell E, Kiemeney LA, Shen H, Haugen A, Johansson M, Grankvist K, Caporaso N, Woll P, Dawn Teare M, Scelo G, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Albanes D, Mak R, Barbie D, Brennan P, Hung RJ, Amos CI, Christiani DC, Lin X. Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. Genet Epidemiol 45(1):99-114, 2021. e-Pub 2020. PMID: 32924180.
- Kim DH, Li X, Bian S, Wei LJ, Sun R. Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia. JAMA Netw Open 4(1):e2034745, 2021. PMID: 33507253.
- Xu, M, Tapia, C, Hajjar, J, Sabir, SH, Colen, R, Nagarajan, P, Aung, PP, Gong, J, Rodon Ahnert, J, Fu, S, Stephen, B, Roy Chowdhuri, S, Le, H, Yang, V, Zarifa, A, Abdelsalam, ME, Jhingran, A, Javle, M, Pant, S, Carter, B, Milton, D, Sun, R, Karp, DD, Koay, EJ, Yang, Y, Wistuba, II, Hwu, P, Meric-Bernstam, F, Naing, A. Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens. Journal of Immunotherapy and Precision Oncology 4(2):45-52, 2021. PMID: 35663531.
- Park, HR, Sun, R, Panganiban, RA, Christiani, DC, Lu, Q. MicroRNA-124 Reduces Arsenic-induced Endoplasmic Reticulum Stress and Neurotoxicity and is Linked with Neurodevelopment in Children. Scientific reports 10(1), 2020. PMID: 32246005.
- Deng, Q, Han, G, Puebla-Osorio, N, Ma, MJ, Strati, P, Chasen, B, Dai, E, Dang, M, Jain, N, Yang, H, Wang, Y, Zhang, S, Wang, R, Chen, R, Showell, J, Ghosh, S, Patchva, S, Zhang, Q, Sun, R, Hagemeister, FB, Fayad, LE, Samaniego, F, Lee, HC, Nastoupil, L, Fowler, N, Davis, RE, Westin, JR, Neelapu, SS, Wang, L, Green, M. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. PMID: 33020644.
- Sun R, Wang Z, Claus Henn B, Su L, Lu Q, Lin X, Wright RO, Bellinger DC, Kile M, Mazumdar M, Tellez-Rojo MM, Schnaas L, Christiani DC. Identification of novel loci associated with infant cognitive ability. Mol Psychiatry 25(11):3010-3019, 2020. e-Pub 2018. PMID: 30120420.
- Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6), 2020. PMID: 33188051.
- Li X, Li Z, Zhou H, Gaynor SM, Liu Y, Chen H, Sun R, Dey R, Arnett DK, Aslibekyan S, Ballantyne CM, Bielak LF, Blangero J, Boerwinkle E, Bowden DW, Broome JG, Conomos MP, Correa A, Cupples LA, Curran JE, Freedman BI, Guo X, Hindy G, Irvin MR, Kardia SLR, Kathiresan S, Khan AT, Kooperberg CL, Laurie CC, Liu XS, Mahaney MC, Manichaikul AW, Martin LW, Mathias RA, McGarvey ST, Mitchell BD, Montasser ME, Moore JE, Morrison AC, O'Connell JR, Palmer ND, Pampana A, Peralta JM, Peyser PA, Psaty BM, Redline S, Rice KM, Rich SS, Smith JA, Tiwari HK, Tsai MY, Vasan RS, Wang FF, Weeks DE, Weng Z, Wilson JG, Yanek LR, (TOPMed) Consortium NTFPM, Working Group TL, Neale BM, Sunyaev SR, Abecasis GR, Rotter JI, Willer CJ, Peloso GM, Natarajan P, Lin X. Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nat Genet 52(9):969-983, 2020. e-Pub 2020. PMID: 32839606.
- Sun R, Lin X. Genetic Variant Set-Based Tests Using the Generalized Berk-Jones Statistic with Application to a Genome-Wide Association Study of Breast Cancer. J Am Stat Assoc 115(531):1079-1091, 2020. e-Pub 2019. PMID: 33041403.
- Zhu, L, Tong, X, Cai, D, Li, Y, Sun, R, Srivastava, DK, Hudson, MM. Maximum likelihood estimation for the proportional odds model with mixed interval-censored failure time data. Journal of Applied Statistics:1-17, 2020. PMID: 34349336.
- Gaynor SM, Sun R, Lin X, Quackenbush J. Identification of differentially expressed gene sets using the Generalized Berk-Jones statistica. Bioinformatics 35(22):4568-4576, 2019. PMID: 31062858.
- Sun R, Hui S, Bader GD, Lin X, Kraft P. Powerful gene set analysis in GWAS with the Generalized Berk-Jones statistic. PLoS Genet 15(3):e1007530, 2019. e-Pub 2019. PMID: 30875371.
- Orkaby AR, Rich MW, Sun R, Lux E, Wei LJ, Kim DH. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc 66(10):1987-1991, 2018. e-Pub 2018. PMID: 30251369.
- Sun R, Carroll RJ, Christiani DC, Lin X. Testing for gene-environment interaction under exposure misspecification. Biometrics 74(2):653-662, 2018. e-Pub 2017. PMID: 29120492.
- Wang Z, Claus Henn B, Wang C, Wei Y, Su L, Sun R, Chen H, Wagner PJ, Lu Q, Lin X, Wright R, Bellinger D, Kile M, Mazumdar M, Tellez-Rojo MM, Schnaas L, Christiani DC. Genome-wide gene by lead exposure interaction analysis identifies UNC5D as a candidate gene for neurodevelopment. Environ Health 16(1):81, 2017. e-Pub 2017. PMID: 28754176.
- Sun R, Bouchard MB, Hillman EM. SPLASSH: Open source software for camera-based high-speed, multispectral in-vivo optical image acquisition. Biomed Opt Express 1(2):385-397, 2010. e-Pub 2010. PMID: 21258475.
- Xu Z, Choi J, Sun R. Set-based tests for genetic association studies with interval-censored competing risks outcomes. Statistics in Biosciences None(None):None. PMID: None.
- Yousef MM, Yousef AM, Fanaeian MM, Chowdhury S, Knafl M, Zeineddine M, Alfaro K, Uppal A, Sun R, Wang W, Singh Raghav KP, Willis J, Kopetz S, YC Shen JP. Understanding Causes of Racial/Ethnic Survival Disparity in 47,178 Patients with Colorectal Cancer: Evaluation of Molecular, Socioeconomic, and Clinical Factors. JAMA Oncol None(None):None. PMID: None.
Letters to the Editor
- Sun R, Wei LJ. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 390: 1939, 2024.
- Sun R, Moraleda JM, Wei LJ. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma. JAMA Oncol 10: 674, 2024.
- Sun, R, Wei, LJ. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?. JAMA Oncology 10: 537, 2024.
- Sun, R, Liu, J, Wei, LJ. Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma. Journal of Clinical Oncology 42: 366-367, 2024.
- Sun, R, Seibert, TM, Wei, LJ. Predictability of Olfactory Neuroblastoma Staging Systems. JAMA Otolaryngology - Head and Neck Surgery 150: 84-85, 2024.
- Sun R, Wei LJ. Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer. JAMA Surg 158: 1357-1358, 2023.
- Sun R, Huang B, Wei LJ. Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer. J Clin Oncol 41: 1952-1953, 2023.
- Sun R, Wei LJ. Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 40: JCO2201084, 2022.
- Sun R, Wei LJ. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. JAMA Oncol 8: 1701, 2022.
- Sun, R, Wei, LJ. Pembrolizumab in Triple-Negative Breast Cancer. New England Journal of Medicine 387: 1435-1436, 2022.
- Sun R, Tian L, Wei LJ. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. JAMA Surg 157: 458-459, 2022.
- Sun R, Messick C, Wei LJ. Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis for Low Rectal Cancers. JAMA Surg 156: 202-203, 2021.
- Sun R, Kim DH, Wei LJ. Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Oncol 6: 1121-1122, 2020.
- Wei LJ, Sun R, Orkaby AR, Kim DH, Zhu H. Biodegradable-polymer stents versus durable-polymer stents. Lancet 393: 1932-1933, 2019.
- Sun R, Zhu H, Wei LJ. Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer. JAMA Oncol 5: 270, 2019.
- Sun R, Wei LJ. Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma. JAMA Oncol 5: 112-113, 2019.
- Sun R, Lee H, Wei LJ. Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma. JAMA Surg 154: 96, 2019.
- Sun R, Nie L, Huang B, Kim DH, Wei LJ. Quantifying Immunoscore performance. Lancet 392: 1624, 2018.
- Sun R, Rich MW, Wei LJ. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med 379: e18, 2018.
- Sun R, Horiguchi M, Wei LJ. Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. J Clin Oncol 36: 1378-1379, 2018.
- Sun R, Wei LJ. Aspirin vs placebo as adjuvant therapy for breast cancer. JAMA None: None.
Grant & Contract Support
| Title: | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche |
| Funding Source: | NIH/NCI |
| Role: | Co-Director, Core 2 |
| Title: | Translating molecular profiles into treatment approaches to target disparities in lymphoma |
| Funding Source: | Leukemia & Lymphoma Society |
| Role: | Co-Leader, Core A |
| Title: | Development of large-scale composite null hypothesis testing approaches to perform translational genetics analyses |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| Title: | Innovative cell therapy approaches for hematological and solid malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | BAF complex deregulation in lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Overcoming adaptive resistance to KRAS inhibition in CRC |
| Funding Source: | NIH/NCI subaward via Massachusetts General Hospital |
| Role: | Co-I |
| Title: | Targeting adaptive and acquired resistance to direct KRAS inhibition |
| Funding Source: | Massachusetts General Hospital |
| Role: | Bioinformatics/Statistics |
| Title: | Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody |
| Funding Source: | NIH/NINDS |
| Role: | Biostatistician |
| Title: | Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | STRATEGIC Alliance Agreement(SIV) |
| Funding Source: | Kite Pharma, Inc |
| Role: | Biostatistician |
| Title: | Recruitment of Established Investigators |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Core Co-Director |
| Title: | Cancer Center Support Grant - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Colorectal Cancer Molecular Subtype Assay Development and Validation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Evaluation of a novel CD79b-targeting chimeric antigen receptor T-cell therapy in patients with relapsed/refractory B-cell lymphomas |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | The Role of Human Esophageal Myofibroblasts in Barrett's Esophagus and Esophageal Adenocarcinoma |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Collaborator |
| Title: | Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Collaborator |
| Title: | Clinical Correlations of ctDNA in Locally Advanced Rectal Cancer |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Adaptive Mutability in Colorectal Cancers Treated with Epidermal Growth Factor Receptor Inhibition |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Delineating the impact of clonal hematopoiesis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Recombinant IL-15, NKTR-255, to inhibit T-cell exhaustion and improve metabolic fitness of CAR T cells |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Biostatician |
| Title: | WRN inhibition in microsatellite instability high colorectal cancer |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Vimentin phospho-malleability is critical for maintaining stemness and metastatic properties |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Tracking Alloreactive T-cells to Improve Efficacy of Allogeneic CAR T-cell Therapy |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | ASH MHFA |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Co-I |
| Title: | Targeting aggressive NK-cell leukemia and other CD94-expressing NK/T-cell lymphoproliferative disorders with CAR T-cell therapy |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | CD38 as a Targetable Antigen in Large B Cell Lymphoma (LBCL) to improve the efficacy CD19 Directed Chimeric Antigen Receptor T (CAR T) Cell Therapy and Mitigate CD19 Negative Relapse |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | Developing Appendix Cancer Specific Chemotherapy: A Molecular & Clinical Approach |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Biostatistician |
| Title: | Targeting SMARCA4 Mutations in Pediatric Burkitt Lymphoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | BC210331: Role of DKK3 in Triple Negative Breast Cancer Tumor Progression and Resistance to Therapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Breast Cancer Moonshot Project 2 |
| Funding Source: | MDACC Moonshots Program |
| Role: | Biostatistician |
| Title: | Implementation of a Geriatric Care Survivorship Intervention in Older Adults who have Completed Curative Intent Therapy for Early-Stage Breast Cancer |
| Funding Source: | MDACC Survivorship IRG |
| Role: | Biostatistician |
| Title: | Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | SIV: STRATEGIC Alliance Agreement |
| Funding Source: | Allogene Therapeutics |
| Role: | Biostatistician |
| Title: | STRATEGIC ALLIANCE Rescuing CD19 CAR T-cell therapy in DLBCL |
| Funding Source: | Sanofi Pharmaceuticals |
| Role: | Co-I |
| Title: | The microbiota-immune axis and response to neoadjuvant chemo(immuno)therapy in triple-negative breast cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | Minimal Residual Disease Assessment in Colorectal Cancer |
| Funding Source: | Guardant Health Inc |
| Role: | Biostatistician |
| Title: | MD Anderson Oropharynx Program - Biostatistics and Data Integration |
| Funding Source: | Stiefel Research Fund |
| Role: | Biostatistician |
| Title: | Validation of biomarkers of autophagic flux in patients with RAS mutant tumors |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | LAB study PRPA 6157280 |
| Funding Source: | Amgen, Inc |
| Role: | Biostatistician |
| Title: | Innovative Statistical Analysis for Genome-Wide Data with General Interval-Censored Outcomes of Oral Health in Childhood Cancer Survivors |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| Title: | Circulating Tumor DNA-Defined Minimal Residual Disease in Colorectal Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Statistician |
| Title: | Microsimulation Modeling to Evaluate the Clinical Effectiveness of Novel Cancer Therapies |
| Funding Source: | Burroughs Wellcome Fund |
| Role: | Co-I |
| Title: | Breast Cancer Moon Shot |
| Funding Source: | The University of Texas MD Anderson Cancer Center Moonshot Program |
| Role: | Biostatistician |
| Title: | MIRA Project 4 - Overcoming PARP inhibitor resistance in patients with breast cancer who have germline BRCA mutations |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Activating p53 for colorectal cancer prevention |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Novel signaling pathways regulating pancreatic cancer pathogenesis |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Environmental health statistics training grant in biostatistics |
| Funding Source: | NIH/NIEHS |
| Role: | Trainee |
| Title: | Biometry/epidemiology training grant in biostatistics |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| Title: | Define driver biology that will lead to effective biomarker-guided therapies for 9p21-loss cancers |
| Funding Source: | NIH/NCI |
| Role: | Core 1 Biostatistics Core Lead |
| Title: | Uncovering Metabolic Rewiring of T cells in Acute Myeloid Leukemia: Spatial Considerations and Therapeutic Opportunities |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| Title: | Deciphering the Role of Interferon gamma Signaling in Mediating Therapeutic Resistance in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| Title: | Listeria-inspired phagosome escape drives STING responses to CD47 blockade |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Collaborator |
| Title: | CD79b-targeting CAR T-cell therapy for B-cell lymphomas |
| Funding Source: | GATEWAY FOR CANCER RESEARCH |
| Role: | Co-I |
| Title: | Multimodal Spatio-Temporal Assessment of Immune Dynamics and Systemic Inflammation Associated with Venetoclax Resistance in Acute Myeloid Leukemia with Deletion 7/7q |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Biostatistician |
| Title: | Integrative Profiling and Therapeutic Targeting of the HLA-E/CD94/NKG2A Axis to Revitalize Immune Responses in Acute Myeloid Leukemia |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Collaborator |
| Title: | A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Biostatistician |
| Title: | Advancing Precision Immuno-Oncology In Biliary Tract Cancers |
| Funding Source: | NIH/NCI |
| Role: | Core C Co-Director |
| Title: | Defining and Manipulating the Colorectal Cancer Microenvironment to Prevent Metastatic Relapse |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| Title: | Define driver biology that will lead to effective biomarker-guided therapies for 9p21-loss cancers |
| Funding Source: | National Cancer Institute |
| Role: | Core 1 Biostatistics Core Lead |
| Title: | CD79b-targeting chimeric antigen receptor T-cell therapy for B-cell lymphomas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | EXTENDing efficacy of systemic therapy with local consolidative therapy for OligoProgressive metastatic disease (EXTEND-OP): A randomized phase II basket trial |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Gut microbiome modulation to reverse antibiotics associated dysbiosis in anti-CD19 CAR-T therapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Integrated Clinical and Preclinical Approach for the Development of Effective Therapy in the Drug Resistant GNAS/KRAS Subtype of Appendiceal Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Core 2: Remodeling the Tumor and the Immune Microenvironment to Eliminate Therapy-Resistant Triple-Negative Breast Cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche |
| Funding Source: | Weill Cornell Medicine |
| Role: | Scientific Rigor Officer- Core 2 Co-Director |
| Title: | Racial genetic mutations disparities effect on colorectal cancer outcomes |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Other Significant Contributor |
| Title: | Listeriolysin O Drives STING Responses to Phagocytosis Checkpoint Blockade |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Collaborator |
| Title: | Listeriolysin O Drives STING Signaling for Systemic Responses to Radiotherapy |
| Funding Source: | American Society for Therapeutic Radiology and Oncology (ASTRO) |
| Role: | Other Significant Contributor |
| Title: | Understanding KRAS Allele Specific Outcomes in Pancreatic Cancer |
| Funding Source: | Pancreatic Cancer Action |
| Role: | Co-Mentor |
| Title: | Tumor frameshift neoantigens mediating immunotherapy response in renal cell carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Delineating the effect of clonal hematopoiesis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Co-I |
| Title: | Development of large-scale composite null hypothesis inference approaches to characterize translationally relevant germline genetic variants in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PD/PI |
| Title: | A multi-ethnic genome-wide association study with whole-exome sequencing to identify common and rare genetic risk factors for hepatocellular carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of Large-Scale Hypothesis Testing Methods for Performing Genetic Meditation Analysis |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PD/PI |
| Title: | Phosphorylation and Dephosphorylation at Vimentin S56 Dictate Cancer Stemness and Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Gut Microbiome Modulation to Reverse Antimicrobial Associated Dysbiosis in CAR T Cell Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Gut Microbiome Modulation to Reverse Antimicrobial Associated Dysbiosis in CAR T Cell Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | CD79b-targeting CAR T-cell therapy for transformed follicular lymphoma |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Co-I |
| Title: | System Biology Approach to Elucidate the Reprogramming of the Immune Tumor Microenvironment by Epithelial-Mesenchymal Plasticity |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Targeted monoclonal antibody to DKK3 for the treatment of pancreatic cancer |
| Funding Source: | Subaward via Stellanova Therapeutics, Inc |
| Role: | Biostatistician |
| Title: | Remodeling the Tumor and the Immune Microenvironment to Eliminate Therapy-Resistant Triple-Negative Breast Cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche |
| Funding Source: | Weill Cornell Medicine |
| Role: | Core 3 Co-director |
| Title: | Prediction of Treatment Failure Following CD19 CAR T-cell Therapy in Large B-Cell Lymphoma by Measurement of Circulating Tumor DNA |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | Adaptive Mutability in Colorectal Cancers Treated with Epidermal Growth Factor Receptor Inhibition |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | A De-escalation protocol using Carboplatin and Paclitaxel in stage 1 triple negative breast cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | Multiple Myeloma in the Hispanic Population: Susceptibility, Clinical Features, and Somatic Profiles |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Consensus Molecular Subtyping Assay as a Predictor of Response to Neoadjuvant Therapy in Rectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Anti-CD79b Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Systematic and functional analysis of tumor-host-microbiome complex interactions during metastasis formation in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of DKK3-Targeted Therapeutic Antibodies for Cancer |
| Funding Source: | Stellanova Therapeutics, Inc |
| Role: | Co-I |
| Title: | A Phase I/II Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Targeting Cyclin Dependent Kinase 9 as an Enhancer of Tumor Immunity and a Regulator of PD-L1 in Gastric Adenocarcinoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Immune features associated with outcome following CD19 CAR T-cell therapy in follicular lymphoma |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Co-I |
| Title: | Targeting the Metabolic and Immune Vulnerabilities of the Dormant Breast Cancer Stem Cell Niche |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A study of dual VEGF/PD-L1 blockade and liver SBRT in locally advanced, unresectable HCC |
| Funding Source: | Massachusetts General Hospital |
| Role: | Biostatistician |
| Title: | Investigating the role of Deltex1 (DTX1) regulatory element mutations in Diffuse Large B-cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | BAF complex deregulation in lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Remodeling the Tumor and the Immune Microenvironment to Impact Chemoresistant Triple-Negative Breast Cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | The MD Anderson CLEAR Program: CLinical trial Equity, Access, and Reimbursement |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistics |
| Title: | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Prediction of Treatment Failure Following CD19 CAR T-cell Therapy in Large B-Cell Lymphoma by Measurement of Circulating Tumor DNA |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | Targeting HER3 Expression in Colorectal Cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | The microbiota-immune axis and response to neoadjuvant chemo(immuno)therapy in triple-negative breast cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | MD Anderson Lymphoma SPORE: Improving Outcomes for Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Core Co-Director |
| Title: | Vimentin phospho-malleability is critical for maintaining stemness and metastatic properties |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Refining and personalizing HER2-directed therapies in metastatic colorectal cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Overcoming adaptive resistance to KRAS inhibition in CRC |
| Funding Source: | Massachusetts General Hospital |
| Role: | Co-I |
| Title: | Integration of dental conditions in public genetic compendiums with data infrastructure development and in vitro follow-up |
| Funding Source: | NIH/NIDCR |
| Role: | PD/PI |
| Title: | Early progression following anti-CD19 CAR T-cell therapy in large B-cell lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Molecular and Imaging Biomarkers of Immunotherapy Response in Advanced Hepatocellular carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Multi-ancestry study of sex disparity in genetic predisposition to lung cancer |
| Funding Source: | NIH/NCI subaward via Baylor College of Medicine |
| Role: | PD/PI |
| Title: | PQ1 Elucidating Molecular Etiology and Biology of Young-Onset Rectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Remodeling the tumor and the immune microenvironment to impact chemoresistant triple-negative breast cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody |
| Funding Source: | NIH/NINDS subaward via Un of Tx Southwestern Med Ctr - Dallas |
| Role: | Biostatistician |
| Title: | BC200470: Optimization of Strategies that Target the PI3K/Akt/mTOR (PAM) Pathway in Triple Negative Breast Cancer (TNBC) |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | BC200254: Development of DKK3-Targeted Therapy for Triple Negative Breast Cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Development of Statistical Methodology to Identify Functional Risk Variants in Whole Genome Sequencing Studies with Interval-censored Outcomes |
| Funding Source: | NIH/NHGRI |
| Role: | PD/PI |
| Title: | Developing patient selection strategies for chemotherapy de-escalation in early-stage triple-negative breast cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Co-I |
| Title: | PPARD Overexpression in Gastric Progenitor Cells Modulates Immunity to Accelerate Carcinogenesis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Development of DKK3-Targeted Therapy to Overcome Treatment Resistance in Triple Negative Breast Cancer |
| Funding Source: | Emerson Collective |
| Role: | Biostatician |
| Title: | BC191486: Therapeutic Targeting of Dikkopf 3 (DKK3) for Triple Negative Breast Cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Paracrine Role of Endothelial Cells in HER3-Mediated Colon Cancer Cell Survival |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome |
| Funding Source: | NIH |
| Role: | Co-I |
| Title: | A phase II and biomarker study of targeting GHR/PD-L1/CTLA-4 in unresectable hepatocellular carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
| Title: | Targeting ganglioside GD2 to overcome chemotherapy-resistance in triple-negative breast cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
| Title: | Selvigaltin, an oral galectin-3 inhibitor, plus atezolizumab and bevacizumab, as first-line therapy in patients with unresectable hepatocellular carcinoma |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Collaborator |
| Title: | Developing A Platform for Prospective Clinical Trials Appendiceal Cancer |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Biostatistician |
| Title: | Safety and efficacy of CD94-targeting CAR T cell therapy in patients with T/NK-cell malignancies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations |
| Funding Source: | MASSACHUSETTS GENERAL HOSPITAL |
| Role: | Collaborator |
| Title: | Enhancing Macrophage Checkpoint Inhibition for the Treatment of Follicular Lymphoma |
| Funding Source: | Memorial Sloan Kettering Cancer Center |
| Role: | Co-I |
| Title: | Optimizing TIL therapy and understanding tumor immune microenvironment in colorectal carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Integrated Clinical and Preclinical Approach for the Development of Effective Therapy in the Drug Resistant GNAS/KRAS Subtype of Appendiceal Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Understanding the interaction of mRNA vaccines and clinical responses to immune checkpoint blockade |
| Funding Source: | Society for Immunotherapy of Cancer |
| Role: | Other Significant contributor |
| Title: | In Situ Generation of GD20 CAR Macrophages to Treat H3K27M Diffuse Midline Glioma |
| Funding Source: | AMERICAN BRAIN TUMOR ASSOCIATION |
| Role: | Other Significant contributor |
| Title: | Restoration of LKB1 expression to sensitize non-small cell lung cancer to radiation and immunotherapy |
| Funding Source: | American Society for Therapeutic Radiology and Oncology (ASTRO) |
| Role: | Biostatistician |
| Title: | COVID mRNA Vaccines as Adjuvants to Immune Checkpoint Blockade |
| Funding Source: | INTL ASSOC FOR THE STUDY OF LUNG CANCER |
| Role: | Collaborator |
| Title: | Restoration of LKB1 expression to sensitize tumors to chemoradiation |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | Biostatistician |
| Title: | Restoration of LKB1 expression to sensitize non-small cell lung cancer to chemoradiation |
| Funding Source: | Astros Foundation Grant Program |
| Role: | Other Significant contributor |
| Title: | CD79b-targeting CAR T-cell therapy for B-cell lymphomas |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Listeriolysin O Enhances Radiation Responses to Phagocytosis Checkpoint Blockade |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | Mentor |
| Title: | Tumor cell lineage state diversity and composition in gastric cancer progression and therapy resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
Patient Reviews
CV information above last modified January 21, 2025